Discovery Laboratories announced the launch of its Afectair airway connector for infants receiving aerosolized medication in neonatal or pediatric intensive care units. The Afectair device simplifies aerosolized medication delivery to critical patients who require ventilatory support such as intermittent mechanical ventilation or continuous positive airway pressure.

The Afectair technology was developed as a component of the Aerosurf (lucinactant for inhalation) development program.  The initial phase of this launch is targeting select neonatal and pediatric critical care centers. This is expected to run through the first quarter of 2013 at which time a broader introduction of Afectair will be introduced.

For more information call (215) 488-9300 or visit